Seer, Inc. (SEER)

NMS – Real Time Price. Currency in USD

1.66

-0.03 (-1.78%)

At close: Mar 27, 2026, 4:00 PM EDT

1.66

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:04 PM EDT

About the company

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Key Executives

Name	Position
Dr. Asim Siddiqui Ph.D.	Senior Vice President of Research & Tech Development
Dr. Omid C. Farokhzad M.D., Ph.D.	Founder, CEO, & Chair of the Board of Directors
Dr. Serafim Batzoglou Ph.D.	Chief Data Officer
Kenny Ross	Chief Operations & Product Officer
Mr. David R. Horn	President,Treasurer & CFO
Mr. Martin Goldberg Ph.D.	Senior Vice President of Product Development
Ms. Marissa Dixon	Chief People Officer